Logo image of CYRX

CRYOPORT INC (CYRX) Stock Fundamental Analysis

NASDAQ:CYRX - Nasdaq - US2290503075 - Common Stock - Currency: USD

6.22  -0.41 (-6.18%)

After market: 6.22 0 (0%)

Fundamental Rating

2

Taking everything into account, CYRX scores 2 out of 10 in our fundamental rating. CYRX was compared to 57 industry peers in the Life Sciences Tools & Services industry. CYRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYRX has reported negative net income.
CYRX had a negative operating cash flow in the past year.
CYRX had negative earnings in each of the past 5 years.
CYRX had negative operating cash flow in 4 of the past 5 years.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -23.72%, CYRX is doing worse than 64.91% of the companies in the same industry.
CYRX has a worse Return On Equity (-39.77%) than 63.16% of its industry peers.
Industry RankSector Rank
ROA -23.72%
ROE -39.77%
ROIC N/A
ROA(3y)-13.69%
ROA(5y)-13.63%
ROE(3y)-24.78%
ROE(5y)-21.69%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

CYRX has a Gross Margin (42.28%) which is comparable to the rest of the industry.
CYRX's Gross Margin has declined in the last couple of years.
CYRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5Y-3.93%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYRX has more shares outstanding than it did 1 year ago.
CYRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CYRX has a worse debt to assets ratio.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.31, we must say that CYRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CYRX (-0.31) is worse than 68.42% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that CYRX is not too dependend on debt financing.
CYRX has a Debt to Equity ratio of 0.44. This is comparable to the rest of the industry: CYRX outperforms 42.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -0.31
ROIC/WACCN/A
WACC7.4%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.70 indicates that CYRX has no problem at all paying its short term obligations.
CYRX has a better Current ratio (5.70) than 77.19% of its industry peers.
CYRX has a Quick Ratio of 5.32. This indicates that CYRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.32, CYRX belongs to the best of the industry, outperforming 80.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.7
Quick Ratio 5.32
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CYRX have decreased strongly by -81.42% in the last year.
The Revenue has decreased by -4.34% in the past year.
The Revenue has been growing by 64.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-81.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.55%
Revenue 1Y (TTM)-4.34%
Revenue growth 3Y43.64%
Revenue growth 5Y64.1%
Sales Q2Q%0.9%

3.2 Future

CYRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.96% yearly.
Based on estimates for the next years, CYRX will show a small growth in Revenue. The Revenue will grow by 5.39% on average per year.
EPS Next Y-3.59%
EPS Next 2Y23.77%
EPS Next 3Y16.82%
EPS Next 5Y11.96%
Revenue Next Year-3.04%
Revenue Next 2Y2.15%
Revenue Next 3Y4.18%
Revenue Next 5Y5.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYRX. In the last year negative earnings were reported.
Also next year CYRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as CYRX's earnings are expected to grow with 16.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.77%
EPS Next 3Y16.82%

More info and screens

0

5. Dividend

5.1 Amount

CYRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRYOPORT INC

NASDAQ:CYRX (2/21/2025, 8:11:34 PM)

After market: 6.22 0 (0%)

6.22

-0.41 (-6.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners103.11%
Inst Owner Change-1.1%
Ins Owners2.69%
Ins Owner Change7.32%
Market Cap307.45M
Analysts76.47
Price Target11.53 (85.37%)
Short Float %4.18%
Short Ratio7.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.47%
Min EPS beat(2)27.66%
Max EPS beat(2)93.29%
EPS beat(4)2
Avg EPS beat(4)-59.74%
Min EPS beat(4)-338.78%
Max EPS beat(4)93.29%
EPS beat(8)4
Avg EPS beat(8)-39.75%
EPS beat(12)5
Avg EPS beat(12)-33.52%
EPS beat(16)6
Avg EPS beat(16)-35.6%
Revenue beat(2)0
Avg Revenue beat(2)-3.2%
Min Revenue beat(2)-4.29%
Max Revenue beat(2)-2.11%
Revenue beat(4)0
Avg Revenue beat(4)-4.8%
Min Revenue beat(4)-8.91%
Max Revenue beat(4)-2.11%
Revenue beat(8)1
Avg Revenue beat(8)-3.09%
Revenue beat(12)1
Avg Revenue beat(12)-4.19%
Revenue beat(16)5
Avg Revenue beat(16)-1.35%
PT rev (1m)0%
PT rev (3m)-10.79%
EPS NQ rev (1m)-1.81%
EPS NQ rev (3m)-8.52%
EPS NY rev (1m)-1.33%
EPS NY rev (3m)9.3%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-1.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.36
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS4.57
BVpS8.47
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.72%
ROE -39.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.28%
FCFM N/A
ROA(3y)-13.69%
ROA(5y)-13.63%
ROE(3y)-24.78%
ROE(5y)-21.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5Y-3.93%
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.94%
Cap/Sales 12.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.7
Quick Ratio 5.32
Altman-Z -0.31
F-Score3
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)131.04%
Cap/Depr(5y)142.93%
Cap/Sales(3y)13.56%
Cap/Sales(5y)13.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-81.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.55%
EPS Next Y-3.59%
EPS Next 2Y23.77%
EPS Next 3Y16.82%
EPS Next 5Y11.96%
Revenue 1Y (TTM)-4.34%
Revenue growth 3Y43.64%
Revenue growth 5Y64.1%
Sales Q2Q%0.9%
Revenue Next Year-3.04%
Revenue Next 2Y2.15%
Revenue Next 3Y4.18%
Revenue Next 5Y5.39%
EBIT growth 1Y-30.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.82%
EBIT Next 3Y29.91%
EBIT Next 5Y20.12%
FCF growth 1Y-33.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-189.27%
OCF growth 3YN/A
OCF growth 5YN/A